Everest Medicines Receives the NMPA’s IND Approval for EVER001 to Treat Renal Diseases
- The NMPA has approved the IND application to initiate the P-I study of EVER001 (BTK inhibitor) in patients with glomerular diseases. The study evaluates the safety, efficacy, PK, and PD of EVER001
- Under a 2021 exclusive license agreement with Sinovent and SinoMab BioScience, Everest holds the global rights to develop, produce and commercialize EVER001 for renal diseases
- The P-I study results showed that the therapy exhibited high selectivity, excellent PK properties, a safety profile, and robust target engagement. The company highlights a long-term growth strategy to advance high-quality treatments for the benefit of patients with unmet demand globally
Ref: PRNewswire | Image: Everest Medicines
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.